Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03924557 · ClinicalTrials.gov registry record · NA
Genotype-guided Supportive Care in Symptom Treatment of Cancer Patients
A NA study, sponsored by University of Florida.
- Terminated
- Registry status
- NA
- Development phase
- 148
- Enrollment target
NCT03924557 is a NA study that was terminated before completion, run by University of Florida. The registered enrollment target is 148 participants.
The verdict
NCT03924557, a NA study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- NA
- Development phase
- 148 participants
- Enrollment target
Study Summary
Cancer patients often require administration of multiple supportive care pharmacotherapies while receiving chemotherapy regardless the type of cancer. Supportive care therapies are commonly prescribed to nearly all cancer patients and could include antiemetics (ondansetron), pain management (opiates), GI protection (PPIs), antidepressants (select SSRIs), anticoagulation (warfarin) and antifungal prophylaxis (voriconazole). These are all are associated with known pharmacogenetic interactions, which in some cases render the drugs ineffective or toxic. This could result in negative impacts on quality of life in patients who are already undergoing complicated and costly anticancer regimens. Pharmacogenetic-guided therapy based on an individual patient's genetic profile could potentially target symptoms for which an individual is uniquely susceptible, guiding use of medications that are most likely to be effective, thereby reducing unnecessary physical complications and financial strain. It is hypothesized that patients in the genotype intervention arm will report lower scores for overall symptom distress as compared to patients in the delayed genotype intervention arm following initiation of chemotherapy.
Interventions
- DIAGNOSTIC_TEST Genotype-guided Supportive Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2019-07-09 |
| Est. Completion | 2021-04-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03924557
The ClinicalTrials.gov registry entry for NCT03924557 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Genotype-guided Supportive Care is the first listed.
NCT03924557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03924557 about?
NCT03924557 is a clinical study titled "Genotype-guided Supportive Care in Symptom Treatment of Cancer Patients". Cancer patients often require administration of multiple supportive care pharmacotherapies while receiving chemotherapy regardless the type of cancer. Supportive care therapies are commonly prescribed to nearly all cancer patients and could include antiemetics (ondansetron), pain management (opiates...
What is the current status of trial NCT03924557?
This trial is currently terminated. It is a NA study. The enrollment target is 148 participants. The study started on 2019-07-09. Estimated completion is 2021-04-13.
What interventions are being tested in trial NCT03924557?
The interventions under investigation include: Genotype-guided Supportive Care (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03924557?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.